Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a SEBI Regulation 30 disclosure notifying the schedule of analyst/institutional investor meetings. It contains no financial statements or results, no management or board changes, no capital/financing updates, no proxy materials, and is simply a regulatory announcement under listing rules. It does not fit any other specific category, so it falls under the fallback “Regulatory Filings” category (Code: RNS).
2026-05-13 English
Attached
Regulatory Filings Classification · 9% confidence The document is an intimation under SEBI Listing Regulations providing the schedule of analyst/investor meetings. It is a regulatory announcement to the stock exchange, not an actual investor presentation, call transcript, or financial report. It simply notifies future events and thus falls under miscellaneous regulatory filings.
2026-05-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q4 and full fiscal year 2026 earnings conference call for Dr. Lal PathLabs. It includes management commentary on financial results, operational highlights, strategic initiatives, and a Q&A session with analysts. The presence of detailed financial metrics such as revenue, EBITDA, PAT, margins, EPS, and discussion of business performance confirms this is a full earnings call transcript. The document is lengthy (15,000 characters) and contains substantive financial data and management discussion, not just a brief announcement or summary. Therefore, it fits the category of a Call Transcript (CT).
2026-05-06 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges disclosing that the promoter and promoter group members have not made any encumbrance on shares during the financial year ended March 31, 2026. It references SEBI regulations related to shareholding and encumbrance disclosures. The content is a regulatory compliance disclosure about share encumbrance status, not a financial report, earnings release, or management discussion. It is a notification related to shareholding and regulatory compliance under SEBI rules. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-04 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges disclosing that certain promoters and promoter group members have not made any encumbrance on shares during the financial year ended March 31, 2026. It references SEBI regulations related to share encumbrance and promoter group definitions. The content is a regulatory disclosure about share encumbrance status, not a financial report, earnings release, or management discussion. It is a compliance announcement under SEBI regulations regarding shareholding and encumbrance. The document length is short (2019 characters) and it is a direct disclosure rather than a report or announcement of a report. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-04 English
General Updates
M&A Activity Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the completion of an acquisition of a subsidiary company. It references compliance with SEBI Listing Obligations and Disclosure Requirements, specifically Regulation 30, which pertains to disclosure of material events. The document is an update on a corporate transaction (acquisition) and does not contain financial statements, audit information, or detailed financial analysis. It is not a full report but an announcement of a corporate event related to M&A activity. Therefore, the appropriate classification is M&A Activity (TAR). The document length is short and it is not a report publication announcement or regulatory filing in the fallback sense, but a specific announcement of a merger/acquisition event.
2026-05-01 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.